Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Acumen Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ABOS
Nasdaq
8731
https://acumenpharm.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Acumen Pharmaceuticals Inc
Is Novo Nordisk (NVO) Stock Outpacing Its Medical Peers This Year?
- Jan 6th, 2023 2:40 pm
Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors
- Jan 4th, 2023 1:00 pm
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2022 Earnings Call Transcript
- Dec 29th, 2022 11:02 am
Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights
- Nov 14th, 2022 9:01 pm
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
- Nov 9th, 2022 9:01 pm
Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022
- Nov 7th, 2022 9:01 pm
Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease
- Nov 1st, 2022 12:00 pm
Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease
- Oct 24th, 2022 12:00 pm
We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
- Sep 8th, 2022 4:44 pm
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2022 Earnings Call Transcript
- Aug 16th, 2022 3:00 am
Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights
- Aug 15th, 2022 8:05 pm
Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022
- Aug 8th, 2022 8:15 pm
Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimer’s disease
- Aug 1st, 2022 2:30 pm
Acumen Pharmaceuticals to Participate in Upcoming Investor and Scientific Conferences
- Jul 26th, 2022 8:15 pm
Hopeful week for insiders who might be regretting buying US$5.7m of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) stock earlier this year
- Jun 8th, 2022 12:00 pm
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2022 Earnings Call Transcript
- May 17th, 2022 2:00 am
Acumen Pharmaceuticals Reports Financial Results for First Quarter 2022 and Business Highlights
- May 16th, 2022 8:05 pm
Acumen Pharmaceuticals to Report First Quarter 2022 Financial Results on May 16, 2022
- May 11th, 2022 9:08 pm
Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals’ New Approach to Treating Alzheimer's Disease
- Apr 27th, 2022 12:00 pm
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2021 Earnings Call Transcript
- Apr 2nd, 2022 4:00 am
Scroll